Results 1 to 10 of about 53,492 (272)
Nature Communications, 2022 Clostridioides difficile infection (CDI) results in significant morbidity and mortality in hospitalised patients. Here the authors engineer probiotics to restore intestinal bile salt metabolism in response to antibiotic-induced microbiome dysbiosis ...
Elvin Koh +7 more
doaj +2 more sources
The Impact of Diet on Clostridioides difficile Infection: A Review. [PDF]
J Infect DisClostridioides difficile poses a significant public health challenge as it is the leading cause of antibiotic-associated diarrhea and is associated with significant morbidity and mortality.
Castro M +4 more
europepmc +2 more sources
Effect of fecal microbiota, live-jslm (REBYOTA [RBL]) on health-related quality of life in patients with recurrent Clostridioides difficile infection: Results from the PUNCH CD3 clinical trial [PDF]
Open Forum Infectious Diseases, 2023 BACKGROUND: Recurrence of METHODS: This was a secondary analysis of a randomized, double-blind, placebo-controlled phase 3 study (PUNCH CD3). The disease-specific RESULTS: Findings were analyzed in a total of 185 patients (RBL, n = 128 [69.2%]; placebo ...
Bancke, Lindy L +10 more
core +3 more sources
Clinical Infectious Diseases, 2021 This clinical practice guideline is a focused update on management of Clostridioides difficile infection (CDI) in adults specifically addressing the use of fidaxomicin and bezlotoxumab for the treatment of CDI.
Stuart Johnson +6 more
semanticscholar +2 more sources
Comparison of fidaxomicin, metronidazole and vancomycin for initial episode and recurrence of Clostridioides difficile infection - An observational cohort study [PDF]
HeliyonObjectives: The main aim of this study was to compare the clinical outcomes of patients attended in our area with Clostridioides difficile infection (CDI) (sustained cure, recurrence or death) in relation to treatment to normal or hypervirulent C ...
Marcos Hernando-Gozalo +4 more
doaj +3 more sources
International Journal of Infectious Diseases, 2022 Recently, the recommendations for the treatment of Clostridioides difficile infection (CDI) have been updated. However, in addition to the clinical efficacy data, the drug of choice should ideally represent optimal antimicrobial stewardship, with an ...
Marcela Krutova, Mark Wilcox, Ed Kuijper
doaj +1 more source
Frontiers in Immunology, 2021 BackgroundClostridioides difficile is a major cause of healthcare-associated and community-acquired diarrhea. Host genetic susceptibility to Clostridioides difficile infection has not been studied on a large-scale.MethodsA total of 1,160 Clostridioides ...
Jiang Li +11 more
doaj +1 more source
SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection.
New England Journal of Medicine, 2022 BACKGROUND Current therapies for recurrent Clostridioides difficile infection do not address the disrupted microbiome, which supports C. difficile spore germination into toxin-producing bacteria.
P. Feuerstadt +22 more
semanticscholar +1 more source
Drugs, 2022 Recurrent Clostridioides difficile infection, associated with dysbiosis of gut microbiota, has substantial disease burden in the USA. RBX2660 is a live biotherapeutic product consisting of a broad consortium of microbes prepared from human stool that is ...
S. Khanna +14 more
semanticscholar +1 more source
Clinical Microbiology and Infection, 2021 SCOPE In 2009, the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) published the first treatment guidance document for Clostridioides difficile infection (CDI). This document was updated in 2014.
J. van Prehn +19 more
semanticscholar +1 more source